A Long-Term Study of Prognosis in Monoclonal Gammopathy of Undetermined Significance
- Study type
- Observational study
- Design
- Long-term population-based cohort study of residents of south-eastern Minnesota, with follow-up for disease progression
- Sample size
- 1384 patients
- Source
- N Engl J Med · 2002
In plain words
Monoclonal gammopathy of undetermined significance (MGUS) is a condition in which an abnormal protein is found in the blood but which is not yet considered cancer. In this study, 1384 patients with MGUS were followed for many years. About 1 percent of patients each year progressed to multiple myeloma or related diseases. The starting amount of abnormal protein in the blood was linked to the chance of the disease progressing.
Key results
Treatment arms and regimens
This is an observational study with no therapeutic intervention. Patients were followed for progression to multiple myeloma or other plasma cell malignancies. Dose details: not applicable.
Source of the regimen details: Abstract of the paper (observational study without drug intervention)
Doses are given for the information of specialists, as in this study’s protocol, and are not a prescription. Every drug must be prescribed by the treating physician for the individual patient.
Study population
1384 residents of south-eastern Minnesota in whom monoclonal gammopathy of undetermined significance (MGUS) was diagnosed at the Mayo Clinic between 1960 and 1994.
Endpoints
Primary endpoint: progression to multiple myeloma or other plasma cell cancers.
Safety and side effects
This is an observational study with no therapeutic intervention; therefore no safety or treatment adverse event data are reported in the abstract.
Clinical significance and place in guidelines
This study provides a long-term estimate of the risk of progression of MGUS (about 1 percent per year) and shows that the initial serum monoclonal protein concentration predicts progression. The abstract gives no information about changes to clinical guidelines or regulatory approvals, and current monitoring recommendations should be checked in authoritative up-to-date guidelines.
Limitations
According to the abstract, patients were residents of south-eastern Minnesota diagnosed at a single centre (Mayo Clinic), and risk was compared with the white population of the Iowa SEER programme; generalisability to other populations should therefore be considered with caution. Other limitations should be checked in the full text of the paper.
This summary was prepared by the editorial team from the published paper; the original paper is the final reference. Read the original abstract on PubMed.